African Americans and Glaucoma
After cataracts, glaucoma is the leading cause of blindness in African Americans. Half of those with glaucoma don’t know they have it.
Menu
Menu
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
After cataracts, glaucoma is the leading cause of blindness in African Americans. Half of those with glaucoma don’t know they have it.
Andrew Huberman, PhD is a principal investigator in the Catalyst for a Cure Biomarkers Team funded by Glaucoma Research Foundation in San Francisco, CA.
The Srinivasan Laboratory at the University of California, Davis, develops novel optical imaging techniques and diagnostics with applications spanning from basic to clinical research.
Dr. Goldberg’s glaucoma research is directed at neuroprotection and regeneration of retinal ganglion cells and other retinal neurons.
Retinal ganglion cells (RGCs) are particularly important in glaucoma because they are the cells that are damaged by the disease.
You and your eye doctor share the same goal in the treatment of glaucoma: to preserve as much of your vision as possible, even if the disease progresses over time.
If you are a glaucoma patient, it is important for you and your doctor to monitor your intraocular pressure (IOP).
Robert Shaffer and his wife Virginia leave behind a remarkable legacy through their generous philanthropic support and lifelong dedication to teaching the next generation of glaucoma specialists.
Vision scientists have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma.
Researchers like Dr. Andrew Huberman and the other Catalyst for a Cure scientists are focused on stopping blindness from glaucoma.
Due to its excellent benefit-to-risk profile, selective laser trabeculoplasty, or SLT, is being offered earlier in the treatment strategy of glaucoma, including as primary therapy.
Q: I’ve heard that glaucoma is caused by high eye pressure, and that left untreated glaucoma can cause blindness. At what pressure will I go blind?
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2022 all rights reserved.
Print Subscription
(The printed edition of the Gleams newsletter is only available if you live in the United States or Canada)
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.